HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA developing "regulatory strategy" for cosmetics with drug effects -- CFSAN plan.

This article was originally published in The Rose Sheet

Executive Summary

CFSAN DEVELOPING "REGULATORY STRATEGY" FOR COSMETICS WITH DRUG EFFECTS, according to a strategic plan recently issued by FDA's Center for Food Safety and Applied Nutrition. In the report, CFSAN states that its goal for the agency's cosmetic program is to develop "a regulatory strategy for cosmetic products with pharmacologic components and effects" over the next five to seven years. The "CFSAN Strategic Plan: 1996-2001" outlines the agency's research and regulatory priorities for all products under its purview for the next five years.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS002588

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel